Glaxo likes Lance a lot: Sean Lance to succeed CEO Sykes in 1998.
GLAXO WELLCOME CEO-DESIGNATE LANCE HEADS INTERNATIONAL BUSINESS of Glaxo Wellcome as managing director of Glaxo Wellcome, plc. Sean Lance, 49, will succeed Richard Sykes, PhD, as chief executive of Glaxo Wellcome at the 1998 annual general meeting. Sykes, currently deputy chairman and chief executive, will assume the chairman spot upon the retirement of Colin Corness in May 1997 and fill both roles for a year.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth